[go: up one dir, main page]

GB202011126D0 - Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy - Google Patents

Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy

Info

Publication number
GB202011126D0
GB202011126D0 GBGB2011126.6A GB202011126A GB202011126D0 GB 202011126 D0 GB202011126 D0 GB 202011126D0 GB 202011126 A GB202011126 A GB 202011126A GB 202011126 D0 GB202011126 D0 GB 202011126D0
Authority
GB
United Kingdom
Prior art keywords
sezures
mutifocal
cannabidiol
epilepsy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB2011126.6A
Other versions
GB2597284A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Research Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Ltd filed Critical GW Research Ltd
Priority to GB2011126.6A priority Critical patent/GB2597284A/en
Publication of GB202011126D0 publication Critical patent/GB202011126D0/en
Priority to PCT/EP2021/069833 priority patent/WO2022017925A1/en
Publication of GB2597284A publication Critical patent/GB2597284A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB2011126.6A 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy Withdrawn GB2597284A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2011126.6A GB2597284A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy
PCT/EP2021/069833 WO2022017925A1 (en) 2020-07-20 2021-07-15 Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2011126.6A GB2597284A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy

Publications (2)

Publication Number Publication Date
GB202011126D0 true GB202011126D0 (en) 2020-09-02
GB2597284A GB2597284A (en) 2022-01-26

Family

ID=72339066

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2011126.6A Withdrawn GB2597284A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy

Country Status (2)

Country Link
GB (1) GB2597284A (en)
WO (1) WO2022017925A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations

Also Published As

Publication number Publication date
WO2022017925A1 (en) 2022-01-27
GB2597284A (en) 2022-01-26

Similar Documents

Publication Publication Date Title
GB201900797D0 (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB201902427D0 (en) Use of cannabinoids in the treatment of epilepsy
GB202014723D0 (en) Use of cannabinoids in the treatment of epilepsy
IL276217A (en) Use of cannabinoids in the treatment of epilepsy
GB2590793B (en) Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy
GB201819573D0 (en) Use of cannabinoids in the treatment of epilepsy
GB202019301D0 (en) Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
GB201907283D0 (en) Use of cannabidiol in the treatment of epileptic spams
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
GB201915522D0 (en) Use of cannabidiol preparations in the treatment of absence epilepsy
GB2564383B (en) Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB201915519D0 (en) Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB201912244D0 (en) Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
GB202102010D0 (en) Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
GB201510664D0 (en) Use of cannabinoids in the treatment of epilepsy
IL286334A (en) Modified micrornas and their use in the treatment of cancer
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB202108690D0 (en) Use of cannabinoids in the treatment of epilepsy
IL274838A (en) Use of mir101 or mir128 in the treatment of seizure disorders
PL3040329T3 (en) Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism
SI3914247T1 (en) Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease
GB202011126D0 (en) Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)